Evidence map›Paper›PMID 32188089›Full record

ArticleMolecules (Basel, Switzerland)2020

The Evolution of Pleconaril: Modified

Alexandrina Volobueva, Anna Egorova, Anastasia Galochkina, Sean Ekins, Vladimir Zarubaev, Vadim Makarov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ACS infectious diseases · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexandrina VolobuevaSaint-Petersburg Pasteur Institute, Mira str., 14, 197101 Saint Petersburg, Russia.
Anna EgorovaBach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky prospect, 33, build. 2, 119071 Moscow, Russia.
Anastasia GalochkinaSaint-Petersburg Pasteur Institute, Mira str., 14, 197101 Saint Petersburg, Russia.
Sean EkinsCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Vladimir ZarubaevSaint-Petersburg Pasteur Institute, Mira str., 14, 197101 Saint Petersburg, Russia.ORCID 0000-0002-5224-3771
Vadim MakarovBach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky prospect, 33, build. 2, 119071 Moscow, Russia.

Funding

Federal Agency for Scientific Organizations 0104-2019-0012
6 · The paper itself

Abstract

Coxsackieviruses type B are one of the most common causes of mild upper respiratory and gastrointestinal illnesses. At the time of writing, there are no approved drugs for effective antiviral treatment for Coxsackieviruses type B. We used the core-structure of pleconaril, a well-known antienteroviral drug candidate, for the synthesis of novel compounds with

Indexed as

AnimalsAntiviral AgentsCell DeathChlorocebus aethiopsDogsEnterovirus B, HumanMadin Darby Canine Kidney CellsOxadiazolesOxazolesPiperazinesVero CellsAntiviral AgentsOxadiazolesOxazolesPiperazinespleconarilantiviralscoxsackieviruscoxsackievirus B3 Nancypleconarilviral myocarditis

Identifiers

PMID32188089
PMCPMC7144106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.